NCT00070499 2026-03-18
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT00792948 2026-03-18
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02143414 2026-03-18
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04971226 2026-03-10
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
NCT00364286 2026-01-20
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00254423 2026-01-15
Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00255346 2025-12-30
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03654768 2025-12-18
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
SWOG Cancer Research Network
Phase 2 Active not recruiting
NCT02883049 2025-11-26
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05198843 2025-10-03
Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT05192889 2025-09-22
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
NCT02420717 2025-06-08
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated